FGEN vs AKBA vs FOLD vs RARE

For growth investors, Akebia Therapeutics, Inc.

(AKBA) is the stronger pick with 47. 5% revenue growth year-over-year, versus -36. 7% for FibroGen, Inc. (FGEN). Analysts rate Akebia Therapeutics, Inc. (AKBA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Amicus Therapeutics, Inc.

(FOLD) delivered a total return of +48. 6%, compared to -98. 5% for FibroGen, Inc. (FGEN). Over 10 years, the gap is even starker: FOLD returned +119. 2% versus FGEN's -98. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.

(FOLD) is the lower-risk stock at 0. 63β versus FibroGen, Inc. 's 1. 58β — meaning FGEN is approximately 151% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Amicus Therapeutics, Inc. (FOLD) carries a lower debt/equity ratio of 176% versus 7% for Akebia Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Akebia Therapeutics, Inc.

(AKBA) is pulling ahead at 47. 5% versus -36. 7% for FibroGen, Inc. (FGEN). On earnings-per-share growth, the picture is similar: Akebia Therapeutics, Inc. grew EPS 93. 7% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, FOLD leads at 24. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Akebia Therapeutics, Inc.

(AKBA) is the more profitable company, earning -2. 3% net margin versus -160. 6% for FibroGen, Inc. — meaning it keeps -2. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AKBA leads at 9. 9% versus -507. 8% for FGEN. At the gross margin level — before operating expenses — FOLD leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for FGEN: 273.

3% to $28. 00.

In this comparison, FGEN (0.

3% yield) pays a dividend. AKBA, FOLD, RARE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Amicus Therapeutics, Inc.

(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), +119. 2% 10Y return). FibroGen, Inc. (FGEN) carries a higher beta of 1. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FOLD: +119. 2%, FGEN: -98. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: FGEN is a small-cap quality compounder stock; AKBA is a small-cap high-growth stock; FOLD is a small-cap high-growth stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.